atorvastatin has been researched along with Fatty Liver, Nonalcoholic in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 32 (74.42) | 24.3611 |
| 2020's | 11 (25.58) | 2.80 |
| Authors | Studies |
|---|---|
| Mukhamejanova, Z; Pang, J; Tong, Y; Wen, T; Xiang, Q; Xu, F; Zhu, W | 1 |
| Baumert, TF; Chung, RT; Corey, KE; Hoshida, Y; Kim, MH; Kim, MY; Lee, Y; Qian, T; Sadreyev, RI; Salloum, S; Shroff, SG; Wong, LP; Xu, M | 1 |
| Bahreini, E; Barzin Tond, S; Fadaei, R; Fallah, S; Farahmandian, N; Karima, S; Koushki, M; Nourbakhsh, M; Rezaei, A; Yarahmadi, S | 1 |
| Augusto, CT; de la Paz Scribano Parada, M; Del Carmen Baez, M; Fonseca, I; Rossi, MM; Signorini, F | 1 |
| Caspers, MPM; Giera, M; Inia, JA; Jukema, JW; Menke, AL; Morrison, MC; Pieterman, EJ; Princen, HMG; Stokman, G; van den Hoek, AM; Verschuren, L | 1 |
| Chen, WM; Chiang, MF; Lee, MC; Lo, HC; Soong, RS; Wu, MS; Wu, SY | 1 |
| Cohen, DE; Freilich, B; Fuchs, M; Hellstern, PA; Kohli, A; Lawitz, EJ; MacConell, L; Owens-Grillo, J; Pockros, PJ; Schiff, E; Shapiro, D; Shringarpure, R; Van Biene, C | 1 |
| Ipsen, DH; Klaebel, JH; Lykkesfeldt, J; Rakipovski, G; Schou-Pedersen, AMV; Skat-Rørdam, J; Skjødt, M; Tveden-Nyborg, P | 1 |
| Abbasi, A; Farhad, N; Zarei, L | 1 |
| Chan, AWH; Chu, ES; Coker, OO; Fu, K; Lau, HCH; Sung, JJY; Wang, YX; Wei, H; Yang, X; Yu, J; Zhang, X | 1 |
| Athyros, VG; Doumas, M; Giouleme, O; Imprialos, K; Karagiannis, A; Koumaras, C; Perdikakis, E; Psallas, M; Sfikas, G | 1 |
| Augustin, S; Barberá, A; Bravo, M; Estrella, F; Genescà, J; Gil, M; Hide, D; Martell, M; Raurell, I; Salcedo, MT | 1 |
| Faistova, H; Faradonbeh, FA; Hroch, M; Hyspler, R; Igreja Sa, IC; Lastuvkova, H; Micuda, S; Mokry, J; Nachtigal, P; Nova, Z; Pavek, P; Schreiberova, J; Stefela, A | 1 |
| Ahmed, S; Jamil, S; Khan, RA | 1 |
| Athyros, VG; Katsiki, N; Mikhailidis, DP | 1 |
| Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A | 1 |
| Gao, H; Hu, Y; Li, X; Tian, R; Wang, Y; Williams, BR; Xu, P; Yan, F; Ying, L; Zhao, Y | 1 |
| Cao, K; Feng, X; Gao, X; Nan, Y; Ren, B; Sun, C; Ye, J; Yu, M; Yuan, Y; Zhao, Y | 1 |
| Chen, Y; Duan, Y; Han, J; Hu, W; Li, L; Li, X; Liu, L; Liu, M; Liu, Y; Miao, QR; Sun, L; Yang, X; Yu, M; Zhang, W; Zhang, X; Zhu, Y | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S | 1 |
| Farrell, GC; Haigh, WG; Ioannou, GN; Savard, C; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Abd Elmaaboud, MA; Albarraq, AA; Kabel, AM | 1 |
| Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Ajamieh, H; Chu, E; Farrell, GC; Lam, W; McCuskey, RS; Teoh, NC; Wong, HJ; Yu, J | 1 |
| Adánez, G; Ayala, I; Castells, MT; García-Pérez, B; Martín, A; Sánchez-Polo, MT | 1 |
| Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A | 1 |
| Klyarytskaya, IL; Maksymova, EV; Stilidi, EI | 1 |
| Fung, KP; Koon, CM; Lau, CB; Lau, CP; Leung, PC; Liu, CL; Ng, CF; Pang, KY; Wat, E; Wong, CW; Zhang, C; Zhang, X | 1 |
| Ahmadi, N; Budoff, MJ; Foster, T; Gordon, C; Guerci, AD; Saab, S | 1 |
| Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L | 1 |
| Allard, JP; Arendt, BM | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X | 1 |
| Hassanian, MA; Samy, W | 1 |
| Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Maeda, S; Yamagishi, S | 1 |
| Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J | 1 |
| Lonardo, A; Loria, P | 1 |
| Gracia-Sancho, J | 1 |
2 review(s) available for atorvastatin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Topics: Allopurinol; Atorvastatin; Biomarkers; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Treatment Outcome; Uric Acid | 2018 |
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin | 2013 |
9 trial(s) available for atorvastatin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Topics: Adult; Aged; Atorvastatin; Bile Acids and Salts; Chenodeoxycholic Acid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; United States | 2019 |
Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Military Personnel; Non-alcoholic Fatty Liver Disease; Prevalence; Rosuvastatin Calcium | 2021 |
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2014 |
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors | 2014 |
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Urban Population; Valsartan | 2015 |
[COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE].
Topics: Adult; Aged; Atorvastatin; Female; Humans; Interleukin-6; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid; Vitamin E | 2015 |
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Antioxidants; Ascorbic Acid; Atorvastatin; California; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin D | 2011 |
Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Confidence Intervals; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pyrroles; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin A | 2011 |
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides | 2011 |
32 other study(ies) available for atorvastatin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR alpha; Proteomics; Pyrans; Signal Transduction | 2022 |
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins c-akt | 2022 |
Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; Cholesterol; Diet, High-Fat; Lipoproteins, LDL; Liver X Receptors; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Resveratrol | 2023 |
Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome.
Topics: Animals; Atorvastatin; Liver; Male; Metabolic Syndrome; Metformin; Models, Theoretical; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Superoxide Dismutase | 2023 |
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation.
Topics: Animals; Apolipoproteins E; Atorvastatin; Cholesterol; Diet; Inflammasomes; Inflammation; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease | 2023 |
Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Non-alcoholic Fatty Liver Disease; Risk Factors | 2023 |
Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Atorvastatin; Caloric Restriction; Combined Modality Therapy; Female; Guinea Pigs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Liver; Liver Cirrhosis, Experimental; Non-alcoholic Fatty Liver Disease; Time Factors; Vitamin E | 2019 |
All-Trans Retinoic Acid (atRA) effectively improves liver steatosis in a rabbit model of high fat induced liver steatosis.
Topics: Animals; Antioxidants; Atorvastatin; Diet, High-Fat; Humans; Hyperlipidemias; Liver; Male; Non-alcoholic Fatty Liver Disease; Rabbits; Tretinoin | 2022 |
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Case-Control Studies; Cholesterol, Dietary; Disease Progression; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2021 |
Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.
Topics: Alanine Transaminase; Animals; Atorvastatin; Biomarkers; Collagen; Disease Models, Animal; Drug Synergism; Endothelial Cells; Endothelin-1; Enzyme Activation; Hemodynamics; Hepatic Stellate Cells; Insulin Resistance; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyridazines; Weight Gain | 2021 |
Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.
Topics: Animals; Atorvastatin; Bile Acids and Salts; Biomarkers; Diet, High-Fat; Disease Models, Animal; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Mice; Models, Biological; Non-alcoholic Fatty Liver Disease; Triglycerides | 2021 |
Anti hyperlipidemic and hepatoprotective effects of native date fruit variety "Aseel" (Phoenix dactylifera).
Topics: Animals; Atorvastatin; Biomarkers; Blood Glucose; Cytoprotection; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Fruit; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Phoeniceae; Phytotherapy; Plant Extracts; Plants, Medicinal; Rats; Time Factors | 2016 |
Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?
Topics: Atorvastatin; Comorbidity; Coronary Disease; Evidence-Based Medicine; Humans; Longitudinal Studies; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Rosuvastatin Calcium; Treatment Outcome | 2017 |
(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease.
Topics: Animals; Atorvastatin; Catechin; Disease Models, Animal; Down-Regulation; Fibrillar Collagens; Gene Expression; Humans; Liver Cirrhosis; Male; Mice, Inbred C57BL; Multigene Family; Non-alcoholic Fatty Liver Disease | 2017 |
Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5.
Topics: Amino Acid Substitution; Animals; Atorvastatin; Cyclic AMP-Dependent Protein Kinases; Dietary Fats; Intracellular Signaling Peptides and Proteins; Lipolysis; Liver; Male; Mice; Mice, Knockout; Muscle Proteins; Mutation, Missense; Non-alcoholic Fatty Liver Disease; Phosphorylation; Triglycerides | 2017 |
Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins.
Topics: Animals; Atorvastatin; Gene Expression Regulation; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver; Liver X Receptors; MAP Kinase Signaling System; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 3; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins c-akt; Receptors, Cell Surface | 2018 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Heptanoic Acids; Inflammasomes; Kupffer Cells; Liver; Mice; Mice, Mutant Strains; Non-alcoholic Fatty Liver Disease; Pyrroles | 2015 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Topics: Animals; Atorvastatin; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Fatty Acids, Omega-3; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin Resistance; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sucrose | 2015 |
Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating eNOS and microparticle formation.
Topics: Animals; Atorvastatin; Chemokines; Cytokines; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Reperfusion Injury; Thromboxane B2; Toll-Like Receptor 4; Vascular Cell Adhesion Molecule-1 | 2015 |
Effect of diet/atorvastatin on atherosclerotic lesions associated to nonalcoholic fatty liver disease in chickens.
Topics: Animals; Arteries; Atherosclerosis; Atorvastatin; Chickens; Diet; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Effect of combined use of Fructus Schisandrae and statin on high-fat-diet-induced metabolic syndrome in rats.
Topics: Animals; Atorvastatin; Cytochrome P-450 CYP3A; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Schisandra | 2016 |
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Disease Models, Animal; Down-Regulation; Fatty Acids; Fatty Liver; Fructokinases; Fructose; Gene Expression Regulation; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; I-kappa B Proteins; Inflammation Mediators; Lipid Metabolism; Liver; Male; Metallothionein; Necrosis; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
Topics: Animals; Atorvastatin; Combined Modality Therapy; Dietary Fats; Fatty Liver; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; Transaminases | 2011 |
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Topics: Adiponectin; Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Collagen Type IV; Dyslipidemias; Fatty Liver; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Regression Analysis; Severity of Illness Index; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4 | 2012 |
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Non-alcoholic Fatty Liver Disease; Pyrroles; Tumor Necrosis Factor-alpha | 2012 |
Enhancing organ pool by statins: is this the future?
Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4 | 2012 |